Full Press Release Details
BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
BBIO
BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Key Takeaway: BridgeBio Pharma Announces U.S. FDA Acceptance Of New Drug Application For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)